Search Results

GE HealthCare Plans $1 Billion Acquisition of Radiopharmaceutical Company Sofie Biosciences

According to reports, healthcare giant GE HealthCare is in talks to acquire radiopharmaceutical company Sofie Biosciences for $1 billion. It is understood that this acquisition will be another major business move for GE HealthCare since its spin-off from General Electric Company in 2023. Previously, the company reached an agreement in March of this year to acquire software company Intelerad for $2.3 billion, aiming to enhance its cloud-based enterprise imaging service capabilities. Sofie Biosciences was founded in 2008 and is headquartered in Dulles, Virginia. The company has a well-established radiopharmaceutical production and distribution network and provides contract manufacturing services. In addition, Sofie Biosci...

2026-09-15

Canada Supports IAEA "Rays of Hope" Initiative for the First Time, Will Provide Medical Isotope Training for Latin America

The Canadian Nuclear Isotope Council (CNIC) announced on September 10 that Canada has for the first time formally provided support to the International Atomic Energy Agency (IAEA) Rays of Hope initiative, and will help enhance cancer diagnosis and treatment capacity in Latin America through training in the production of medical radioisotopes and radiopharmaceuticals. The Rays of Hope initiative aims to expand access to cancer treatment and radiotherapy infrastructure in low- and middle-income countries. Under the arrangement, from November 8 to 14, 26 relevant sector leaders from Argentina, Brazil, Chile and Mexico will travel to Ontario, Canada, to participate in a training program jointly organized by Bruce Power and McMaster University. The training will focus on medical isotopes...

2026-09-11

South Korea's First Animal Radiopharmaceutical Approved for the Treatment of Feline Hyperthyroidism

The Korea Atomic Energy Research Institute announced on September 10 that Thyrokitty Injection (I-131), a radiopharmaceutical for the treatment of feline hyperthyroidism developed by the research team led by Dr. Lim Jae-cheong, has obtained an animal drug manufacturing license issued by the Animal and Plant Quarantine Agency of South Korea. This is South Korea's first animal radiopharmaceutical to receive final product approval, marking the transition of related technologies that had previously been mainly at the R&D stage into clinical therapeutic application for pets. Feline hyperthyroidism is a relatively common endocrine disease in older cats, mainly characterized by excessive secretion of thyroid hormones. According to reports, approximately 10% of cats aged 10 and above may suffer from this disease. Traditional treatment methods typically require...

2026-09-10

ITM and SpiroChem Announce Strategic Collaboration to Advance Novel Radiopharmaceutical Development

Garching/Munich, Germany and Basel, Switzerland, September 8, 2026 – Radiopharmaceutical biotechnology company ITM Isotope Technologies Munich SE and Swiss collaborative research organization SpiroChem AG today announced a strategic drug discovery partnership focused on a novel radiopharmaceutical candidate within ITM's pipeline. The specific target and financial terms of the collaboration were not disclosed. Under the agreement, the parties will combine their respective capabilities to advance candidate discovery and optimization. SpiroChem will leverage its drug discovery platform, macrocycle library, and screening engine to lead hit identification and optimization, while ITM will provide...

2026-09-09

BESIII Experiment Achieves High-Precision Measurement of Charm Meson Semileptonic Decays and First Constraint on "Scalar Current"

Recently, the BESIII international collaboration utilized the world's largest near-threshold charm meson data sample to perform a combined measurement of four semileptonic decay channels: D⁰→K⁻e⁺νₑ, D⁰→K⁻μ⁺νμ, D⁺→K̄⁰e⁺νₑ, and D⁺→K̄⁰μ⁺νμ. The research team extracted the quark mixing matrix element |Vcs| with a precision better than 0.5%, determined the form factor zero-point value f₊(0) with a precision better than 0.2%, and verified lepton universality in the above processes at the 0.5% precision level. Beyond these precise determinations of Standard Model parameters, what is particularly noteworthy is that this experiment has, for the first time...

2026-09-08

Armenian NPP Unit 2 Reconnected to Grid After Overhaul

September 3 news, Armenian Minister of Territorial Administration and Infrastructure David Khudatyan stated that Unit 2 of the Armenian Nuclear Power Plant has resumed operation and been connected to the country's unified power grid after completing a five-month planned overhaul. Khudatyan said that on September 1, 2026, Unit 2 of the Armenian Nuclear Power Plant was restarted after scheduled maintenance and connected to the national unified power grid. Currently, the unit is operating normally, with power output gradually increasing in accordance with established process requirements. The planned overhaul began on April 1 and lasted 153 days as scheduled. During the overhaul, approximately 20 measures were implemented at the plant to enhance unit reliability, safety, and operational efficiency...

2026-09-08

South Korea's DuChemBio to Build Country's First Radiopharmaceutical CDMO Plant

South Korean radiopharmaceutical therapy company DuChemBio will build the country's first contract development and manufacturing organization (CDMO) plant dedicated to radiopharmaceuticals, in response to growing demand for radiopharmaceuticals used in the diagnosis and treatment of cancer and neurological diseases. DuChemBio is a subsidiary of healthcare distributor Geo-Young Group. The company recently signed an investment agreement with North Jeolla Province and the city of Jeongeup to invest KRW 34.3 billion (approximately USD 25.5 million) in building a new plant in Jeongeup. The company stated that this is the largest investment since Geo-Young acquired DuChemBio. According to the plan, the new facility will integrate radioisotope production...

2026-09-08

Atom High-Tech Signs Memorandum of Cooperation with Cambodia's Calmette Hospital and Others to Advance Nuclear Medicine Capacity Building

On September 4, Atom High-Tech, Cambodia's Calmette Hospital, and FFS Company held a trilateral memorandum of cooperation signing ceremony in Beijing. Huo Yingying, Deputy Secretary of the Party Committee of China Isotope & Radiation Corporation (CIRC), attended and delivered a speech, while Zhang Yiming, Secretary of the Party Committee and Chairman of Atom High-Tech, signed on behalf of the company. Established in 1950, Calmette Hospital is one of Cambodia's largest and most technologically advanced public hospitals and serves as a national referral center. It undertakes three core missions: delivering high-quality medical services, training health professionals, and conducting medical research. Currently, the hospital is actively advancing its nuclear medicine capacity by establishing the country's first nuclear medicine department, further improving its oncology diagnosis and treatment and molecular imaging service systems...

2026-09-07

Baiyunshan Xike Visits Jiujiang, Jiangxi to Explore Nuclear Medicine Industry Chain Cooperation

Recently, a delegation from Guangzhou Baiyunshan Xike Health Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Holdings Limited (GP Corp.), visited Jiujiang City, Jiangxi Province, conducting field inspections and discussion exchanges in Ruichang City, Jiujiang Economic Development Zone, and Pengze County, focusing on cooperation across the full nuclear medicine industry chain. Liu Hong, Director of the Scientific Research Project Management Department of GP Corp. and Chairman and General Manager of Baiyunshan Xike, led the core team in exchanges with Chen Shuilian, Member of the Party Leadership Group and Vice Mayor of Jiujiang Municipal People's Government, as well as responsible officials from Ruichang City, Pengze County, and Jiujiang Economic Development Zone, reaching multiple consensuses on subsequent cooperation. The inspection covered key facilities including the Ruichang Institute of Nuclear Physics Applications, the Biomedical (Nuclear) Industrial Park in Jiujiang Economic Development Zone, and the Jiangxi Tianhong Nuclear Technology project site in Pengze County. The delegation conducted in-depth visits to research laboratories, industrial parks, and projects under construction to understand local capabilities in nuclear technology research, isotope R&D infrastructure, project construction progress, as well as land and industrial supporting conditions.

2026-09-07

Canada's AtomVie Opens Large-Scale Radiopharmaceutical R&D and Manufacturing Facility in Hamilton

On September 4, AtomVie Global Radiopharma, a radiopharmaceutical contract development and manufacturing organization, announced the official opening of its new state-of-the-art production facility at 10 Aeropark Boulevard, Hamilton, Ontario, Canada. The facility is designed to support the full-spectrum translation of radiopharmaceuticals from early-stage research and development, through clinical development, to commercial manufacturing. According to reports, the new facility represents an investment of over $160 million and spans 72,300 square feet, making it one of the largest single-site radiopharmaceutical R&D CDMO facilities in North America. The facility offers production capabilities ranging from low-throughput to high-throughput, increasing AtomVie's overall production capacity by more than tenfold, with dedicated spaces configurable to meet clients' subsequent R&D and commercialization needs.

2026-09-05

Armenia to Discuss New Nuclear Power Plant Options with Rosatom

Armenian Prime Minister Nikol Pashinyan stated at a press conference on September 3 that Alexey Likhachev, Director General of Rosatom, will visit Armenia in September, and the two sides will discuss possible options for constructing a new nuclear power plant within Armenia. Pashinyan noted that Armenia expects Likhachev's visit to bring forward Russia's specific proposals regarding the construction of a new nuclear power plant in Armenia. He said that Armenia will prioritize economic viability and project pricing when selecting a nuclear power project, aiming to secure the most cost-effective construction plan. In May of this year, the Russian side had indicated...

2026-09-04

Fire alarms triggered nine times in four weeks at Japan's Fukushima Daiichi Nuclear Power Station

At 21:44 on September 3, a fire alarm was triggered in the water treatment control room building of Japan's Fukushima Daiichi Nuclear Power Station. Tokyo Electric Power Company (TEPCO) stated that no open flames or smoke were found at the scene. After firefighters arrived and conducted inspections, it was confirmed shortly after 22:30 that evening that this was not a fire. TEPCO said it would subsequently inspect the relevant detectors. Including this incident, the Fukushima Daiichi Nuclear Power Station has triggered a total of nine fire alarms in the past four weeks. Previously, on August 8, a fire alarm was triggered in the maintenance building for Units 5 and 6; on August 12, an alarm sounded in the emergency diesel generator room for the high-pressure core spray system of Unit 6; on August 13, an alarm sounded in the main office building; on August 15, an alarm sounded in the southwest stairwell area of the turbine building for Unit 5...

2026-09-04

Qinshan Nuclear Power Completes Overhaul Validation of Grille Cleaning Robotic Arm

The grille cleaning robotic arm, an integrated system of UAV-based intelligent inspection and robotic arm automatic cleaning independently developed by the Mechanical Team of the Fourth Maintenance Division at Qinshan Nuclear Power, recently completed on-site validation during the Unit 2 312 overhaul at Qinshan Phase II. Designed for seawater system intake grille cleaning scenarios, this equipment transforms the original manual operation requiring entry into deep wells into an unmanned operation conducted under ground-based remote monitoring. The intake grille serves as a critical barrier for the cooling water system of a nuclear power plant, and its unobstructed condition is directly related to the stable operation of the unit. In traditional cleaning methods, workers were required to enter narrow shafts more than twenty meters underground to perform inspection and cleaning in confined spaces, which involved high labor intensity, low efficiency, and safety risks such as falls from height...

2026-09-03

Canada's Devonian Integrates HPLC-MS, NMR, and Cell-Based Potency Assays into Thykamine Quality Control Platform

Devonian Health Group Inc., a Canadian clinical-stage biopharmaceutical company, recently announced that it has completed independent validation of key analytical methods and biological quality control technologies and integrated them into the extraction and production process of Thykamine, the company's lead active pharmaceutical botanical candidate. According to the company, its quality control program includes validated high-performance liquid chromatography-mass spectrometry (HPLC-MS) chemical fingerprinting, nuclear magnetic resonance (NMR) spectroscopy, and cell-based biological potency assays based on the U937 human cell line. The relevant cell-based assays use macrophage inflammatory protein-1β (MIP-1β) as a biomarker of Thykamine's anti-inflammatory activity...

2026-09-02

Dankook University Hospital Introduces Next-Generation Digital PET-CT System to Enhance Precision Diagnosis of Cancer and Other Diseases

Dankook University Hospital announced on September 1 that it has introduced GE HealthCare's next-generation digital PET-CT system, the OMNI Legend 32, to enhance precision diagnostic capabilities for a wide range of diseases, including cancer, brain disorders, and cardiac conditions. PET-CT is an important nuclear medicine diagnostic imaging modality. During the examination, a radiopharmaceutical is injected into the patient, and the system observes metabolic activity through positron emission tomography (PET) while simultaneously confirming anatomical structures via computed tomography (CT), thereby providing imaging evidence for clinical diagnosis. According to the hospital, the newly introduced OMNI Legend 32 employs AI-based image reconstruction technology to visualize small lesions with greater clarity, assisting physicians in making more accurate assessments...

2026-09-01